Low disability accumulation after 4-year ocrelizumab therapy in treatment-naive patients with early-stage relapsing-remitting multiple sclerosis; data from the Phase IIIb ENSEMBLE study
MULTIPLE SCLEROSIS JOURNAL（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要